Background: Progression-free survival is an increasingly popular surrogate end point for overall survival. The strength of correlation between the two end points varies, raising questions about the correlation between results of interim analyses that report mature progression-free survival data with the subsequent final publication that report overall survival.
Introduction
If a "game changer" drug is only tested in mice, we should call it what it is: a game changer for mice.
Vinay Prasad
In medical research, hype is the early excitement surrounding promising interventions, despite a lack of substantial supporting evidence [1] . Hype often opposes reason, but it is common, such as when cancer drugs are heralded as 'game changers' despite having been evaluated only in animals and not having received Food and Drug Administration (FDA) approval. Journalists often perpetuate such hype, though physicians may also be responsible [2] .
Cancer researchers perpetuate hype by casting unfavorable (nonsignificant) results in a favorable light [3, 4] . This dangerous practice leads physicians to overstate a drug's efficacy [5] .
We argue that hype affects the oncology community in particular owing to the prevalence of surrogate end points. The popularity of surrogate end points among oncology trial sponsors and investigators has been met with caution from others in the medical community [6] [7] [8] . This skepticism exists because surrogate end points often fail to predict the clinical end points that are most important to patients: overall survival (OS) and quality of life [9] [10] [11] . Nevertheless, most new drugs that receive accelerated approval from the FDA are analyzed using surrogate end points [11] , and the market price for drugs approved based on surrogate end points does not differ from the price of drugs approved based on OS [12] . When drugs granted accelerated approval report the required follow-up data, it is frequently for another surrogate end point, which can generate hype [13] . The current process for drug approvals means that formal assessments of OS may be delayed until after the drug has been widely used in patient care.
One increasingly popular surrogate end point for OS is progression-free survival (PFS). PFS is a composite end point that combines assessments of tumor progression and death from any cause [14] . In oncology studies, the strength of association between PFS and OS varies and depends on tumor type, tumor stage, and drug intervention [15, 16] . A recent study showed that effect sizes are significantly larger for PFS than for OS [17] . PFS requires less time and fewer patients to achieve statistical power. Thus, although oncology trials often report both PFS and OS, they may publish the mature PFS data apart from the mature OS data. Publishing interim trials with only mature PFS data apart from the confirmatory analyses of OS may promote hype.
In this investigation, we analyzed the hype generated by oncology clinical trials that published interim analyses. We investigated whether significant differences existed between interim and final analyses, with respect to the Altmetric score and journal prominence. We restricted our sample to trials that assessed both PFS and OS, because a recent analysis of interim results excluded these trials [18] . . We placed no restriction on included journals. All records were gathered in a PubMed collection.
Methods and materials
Next, we exported this collection of 393 records to Rayyan [19] . We excluded any record that was not a randomized clinical trial, trial protocols, trials that did not assess both PFS and OS, and any record not available in English. To be included, a randomized clinical trial must have reported mature PFS data and denoted their OS data as immature. We further included any trials in which OS not denoted as immature but in which the prespecified number of deaths had not occurred. If we identified a trial reporting final or updated OS results, we attempted to identify the interim analysis with PFS data.
To match interim analyses with their corresponding final analyses, we used a combination of a PubMed search using the PICO (population, intervention, comparator, outcome) format, review of clinical trial registries, and emails to corresponding authors. If an author did not respond to our email, we sent two additional emails at 1-week intervals. Our flow diagram details the process of identifying articles and our exclusion criteria (supplementary Figure S1 , available at Annals of Oncology online).
One of us (CW) independently extracted the following data from each interim and final analysis: title, year of publication, journal, intervention drug, comparator drug(s), whether a PFS benefit was demonstrated, median survival times and hazard ratio (HR), cancer, cancer setting, trial funding source, trial design (e.g. superiority or noninferiority), whether an interim analysis was prespecified, and number of required PFS and OS events to achieve statistical power. All data were extracted via a piloted and validated Google Form. We retrieved the Altmetric score for each interim and final analysis using the 'Altmetric it' bookmarklet, which identified the Altmetric score for each trial from PubMed.
To compare the interim and final analyses, we identified whether a PFS or OS benefit was demonstrated. Authors reported HRs with confidence intervals most often. We calculated the ratio of hazard ratios (rHRs) between PFS and OS (HR-PFS/HR-OS) to determine whether the HR effect size favored PFS or OS. This method was derived from a recent analysis of PFS and OS HR effect sizes [17] . As needed, the direction of effect was stabilized so that an HR less than 1.0 favored the intervention. This convention means that an rHR of less than 1.0 indicates a larger effect size for PFS compared with OS.
We further asked whether the publication of an interim analysis, apart from its final OS analysis, was justified based on the strength of the correlation between PFS and OS. To answer that question, we searched the literature to determine the strength of the correlation between the two end points for the specific tumor, tumor setting, and drug class. We began by referencing a systematic review of the correlation between surrogate end points and OS in oncology [11] . For any tumors, tumor settings, or drug classes that were not included, we searched PubMed (Medline) using the PICO format. We considered a strength of correlation of r 0.7 to be low, 0.7 < r < 0.85 to be medium, and r 0.85 to be high, based on Prasad et al.'s systematic review, which adapted the Institute of Quality and Efficiency in Health Care's convention for trial-level correlation [11, 20] .
We used the Wilcoxon signed-rank test for matched pairs to compare differences in continuous variables and Fisher's exact test to compare differences in categorical variables. For our rHR analysis, visual inspection of the histogram and results from the Shapiro-Wilk test of normality indicated that the data were not normally distributed. Therefore, we report a median rHR and use this median to determine the median-effect size difference between PFS and OS. We used Stata 13.1 for all statistical analyses.
Results
Our search of PubMed retrieved 393 records. Supplementary Figure S1 , available at Annals of Oncology online itemizes the 360 excluded records. We identified 27 interim analyses with mature PFS data, and we found an additional 6 via final analyses with mature OS data from our search. Of the 33 interim analyses with mature PFS data identified, only 25 could be paired with a final analysis. We excluded two of these matched pairs, because their final analyses were either in an abstract or in-press in a journal without an impact factor. The eight unmatched interim analyses have not yet published mature OS data. Therefore, 23 matched pairs were included. Unless otherwise specified, our results are for the 23 interim analyses with a final analysis pairing.
All interim analyses (n ¼ 33) were prespecified and conducted in accordance with that trial's protocol (supplementary Table S1 , available at Annals of Oncology online). A statistically significant PFS benefit occurred in 93.9% (31/33) of interim analyses. At long-term follow-up, the PFS effect size decreased in eight trials (two became nonsignificant), increased in five trials, and remained the same in one. Eleven trials did not report updated PFS data. A statistically significant benefit in OS occurred only 8 times, although 12 trials allowed crossover and 2 administered additional therapies to patients after progression. In the two interim analyses with a statistically nonsignificant PFS benefit, a statistically significant OS benefit occurred in one of them. That trial compared concurrent and sequential alternating gefitinib in previously untreated metastatic non-small-cell lung cancer [21] . Across all studies (n ¼ 33), to achieve statistical power, the median number of required patient events was 282. Among matched pairs (n ¼ 23), interim analyses were published in more prominent journals compared with final analyses (Table 1) . Specifically, interim analyses were more likely to be published in the top 5 general medicine journals (e.g. New England Journal of Medicine, The Lancet) but not more likely to be published in the top 5 oncology journals (e.g. Journal of Clinical Oncology, The Lancet: Oncology). Interim analyses were published in journals with an impact factor of 20 more often, but this difference was not statistically significant. The median impact factor was 44 (IQR 24-72) for journals publishing interim analyses versus 24 (IQR 11-34) for journals publishing final analyses. Only two interim analyses were published in journals with an impact factor less than 10, compared with six final analyses; one final analysis was published as an abstract, and one was an inpress manuscript. The impact factor increased once and remained the same three times from interim to final publication.
Interim analyses also had higher Altmetric scores than final analyses. The median Altmetric score was 28 (IQR 13.25-82.25) for interim analyses versus 18 (5-46) for final analyses (p ¼ 0.002). Of the two final analyses that had no Altmetric scores or impact factors, one was an abstract and one was an in-press manuscript in ESMO: Open. The Altmetric score increased three times and remained the same one times from interim to final analyses.
We were able to compare PFS and OS effect sizes in 24 trials. The PFS effect size was larger than the OS effect in 21 of 24 (87.5%) trials. When comparing the mature PFS data from interim analyses and the mature OS data from final analyses, the median rHR was 0.69 (0.51-0.86), corresponding to a median 31% larger effect size for PFS compared with OS ( Table 2) In 19 of the 25 total matched pairs, there was a low (r 0.7) or unknown strength of correlation between PFS and OS ( Table 2) . In three cases, the strength of correlation was medium (0.7 < r < 0.85). In three other cases, the strength of correlation was high (r 0.85). For the eight interim analyses that had yet to report final OS data, the strength of correlation between PFS and OS was low in five and medium in three. All eight unmatched interim analyses were published in New England Journal of Medicine (n ¼ 3), The Lancet:
Overall, New England Journal of Medicine published the most interim analyses of PFS (n ¼ 9), all of which were statistically significant (supplementary Table S2 , available at Annals of Oncology online). Only two nonsignificant interim analyses of PFS were published-one in The Lancet: Oncology and one in Annals of Oncology. For final analyses of OS, The Lancet: Oncology published the most (n ¼ 7), of which five were statistically significant.
Discussion
Our results demonstrate that interim analyses with mature PFS data generate hype in oncology. Compared with final analyses, n/a n/a a Two were excluded from overall matched pair analysis due to publication as an abstract or for being in-press in a journal without an impact factor. The in-press matched pair is included in the stratified analysis but its impact factor is shown as 'n/a.' PFS, progression-free survival; OS, overall survival. interim analyses are more likely to be published in top-5 general medical journals and more likely to have higher Altmetric scores. Two factors help to explain these differences. PFS was more likely to be statistically significant and have a larger effect size. Additionally, two recent investigations show that interim analyses in oncology are associated with exaggerated effect sizes and that PFS effect sizes are larger than OS effect sizes [17, 22] . Another investigation found that for FDA-approved drugs, the post-approval trials frequently have smaller treatment effects compared with their matched pre-approval trials [23] . Lastly, Woloshin et al. [18] found that one-fifth of final analyses fail to agree with the conclusions of the interim analyses. This last study suggests that no significant difference exists between interim and final publications regarding journal prominence and Altmetric score. Our results show the opposite. We believe that hype in the oncology literature is easier to generate than in the overall medical literature for several reasons. First, most current FDA approvals are for oncology drugs [24] . Also, social and governmental pressure creates a sense of urgency among the oncology community to make cancer therapies available to patients [25] . Moreover, a large treatment effect often causes excitement, especially given the knowledge that recently approved cancer drugs improve OS by a median of only 2 months [26] . Nevertheless, our results should not discourage the analysis of surrogate end points. Instead, they should encourage the proper presentation of surrogate end point results.
The publication of interim analyses with only mature PFS data apart from confirmatory OS analyses must be cautioned. We have demonstrated that the PFS effect sizes are frequently exaggerated compared with the final OS analyses, and that OS fails to confirm a significant PFS benefit in most cases. On the contrary, recent investigations of the correlation between PFS and OS in Programmed cell death protein-1 inhibitor immunotherapy trials showed the opposite-that PFS effect sizes were smaller compared with OS effect sizes [27] . Moreover, in two cases-one investigating bevacizumab in ovarian cancer and one investigating perioperative FOLFOX4 in metastatic colorectal cancer-the significant PFS effect from the interim analyses became nonsignificant at follow-up [28, 29] .
The clinical relevancy of inhibited tumor growth, which likely contributes to the often-exaggerated PFS effect size, is relevant to patients only if the OS benefit follows. Our data show that the mature PFS data in interim analyses were more often statistically significant than subsequent OS data. Crossover was allowed after disease progression in 12 of the included trials and 2 trials administered additional interventions-which may mask true OS benefits. Whether crossover after disease progression is an acceptable feature of trial design has been debated recently [30] [31] [32] .
We further demonstrated that the incidence of publishing interim analyses separately from their final confirmatory analyses has steadily increased. Numerous manuscripts have called for caution when interpreting surrogate end point data [6-9, 11, 33] . Our results support this cautionary call: only 3 of the 33 included interim analyses showed that PFS strongly correlated with OS. For any cancer, cancer setting, or drug intervention without a validated correlation of PFS and OS, the interim publication of PFS data without accompanying OS data is not just unreliable, but likely to generate hype. We, therefore, recommend caution when reading interim analyses with only PFS data, since the effect size and clinical benefit may not be corroborated by future OS data.
Analyses of surrogate end points likely affects clinical decision making. A recent review of FDA drugs that received accelerated approval in the last 25 years showed that all were approved based on a surrogate end point and that most received regular approval based on another surrogate end point [13] . The strength of correlation between surrogate end points and OS could be high for many of these drugs, but it is more likely that the OS effect size is small or null. To be certain, adding even 2 months to a patient's life cannot be discounted and is incredibly important, but patients often expect much more when choosing between treatment options [34] . One must question how the perceived survival benefit demonstrated by surrogate end points affects physician and patient expectations around treatment decisions.
The limitation of our study is that our results are not generalizable to all surrogate end points, because they may correlate with OS differently and may be published apart from OS analyses more or less frequently. Further, the magnitude of difference in Altmetric scores between interim and final analyses may be biased, because the final analyses were published more recently. However, only six final analyses were published in 2017 or later, and one was in-press at the time of analysis and thus excluded. Of the five that were included, three had Altmetric scores well above the median (69, 60, and 43). We are therefore confident that the bias due to time of publication is minimal.
To conclude, we do not discourage the use of surrogate end points in oncology. They are valuable and serve a useful purpose. We do, however, encourage the proper presentation of surrogate end point results in oncology. PFS effect sizes are frequently larger than OS effect sizes, and PFS is infrequently validated as a surrogate end point for OS. We recommend caution when encountering an oncology trial with only immature OS data, because we have demonstrated that such interim analyses may generate unsupported and inappropriate hype. When these interim analyses are published, the journals should provide timely links to the final publication, even if it is published in a different journal.
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